Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454896
Status:
COMPLETED
Last Update Posted:
2014-09-18
First Post:
2007-03-29
Brief Title:
A Multicenter VESIcare Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder OAB
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare for the Treatment of Urgency Associated With Overactive Bladder
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VENUS
Brief Summary:
The purpose is to evaluate the efficacy of 5 and 10mg VESIcare solifenacin succinate in patients with urgency who have overactive bladder syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None